These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32100826)

  • 21. Selected Articles from This Issue.
    Clin Cancer Res; 2020 May; 26(10):2279. PubMed ID: 32414759
    [No Abstract]   [Full Text] [Related]  

  • 22. Tumor Mutational Burden Guides Therapy in a Treatment Refractory
    Bhangoo MS; Boasberg P; Mehta P; Elvin JA; Ali SM; Wu W; Klempner SJ
    Oncologist; 2018 May; 23(5):518-523. PubMed ID: 29386312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Administration of Immune Checkpoint Inhibitor for Cancer except for Melanoma and Lung Cancer].
    Takeda T; Hattori N; Takeda T; Noda T; Takeda H
    Gan To Kagaku Ryoho; 2016 Oct; 43(10):1271-1273. PubMed ID: 27760957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A coming of age for immune checkpoint inhibitors in cancer.
    Nipp RD; Gainor JF
    Immunotherapy; 2019 Jun; 11(8):647-650. PubMed ID: 31088238
    [No Abstract]   [Full Text] [Related]  

  • 25. Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.
    Signorelli D; Giannatempo P; Grazia G; Aiello MM; Bertolini F; Mirabile A; Buti S; Vasile E; Scotti V; Pisapia P; Cona MS; Rolfo C; Malapelle U;
    Biomed Res Int; 2019; 2019():9056417. PubMed ID: 31179334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Editorial (Thematic Issue: The Predictive Pathology in the Target Therapy Era).
    Franco R; Cantile M
    Curr Drug Targets; 2017; 18(1):2-3. PubMed ID: 27991404
    [No Abstract]   [Full Text] [Related]  

  • 27. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
    Meng X; Huang Z; Teng F; Xing L; Yu J
    Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.
    Gandara DR; Paul SM; Kowanetz M; Schleifman E; Zou W; Li Y; Rittmeyer A; Fehrenbacher L; Otto G; Malboeuf C; Lieber DS; Lipson D; Silterra J; Amler L; Riehl T; Cummings CA; Hegde PS; Sandler A; Ballinger M; Fabrizio D; Mok T; Shames DS
    Nat Med; 2018 Sep; 24(9):1441-1448. PubMed ID: 30082870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Exploring the Possibility of New Biomarkers of Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer (NSCLC)].
    Owada Y; Inoue T; Watanabe Y; Fukuhara M; Yamaura T; Muto S; Matsumura Y; Hasegawa T; Tanaka D; Kanno R; Ito E; Nanamiya H; Imai J; Isogai T; Watanabe S; Suzuki H
    Gan To Kagaku Ryoho; 2017 Sep; 44(9):763-766. PubMed ID: 28912405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment.
    Jiang Y; Mackley H; Cheng H; Ajani JA
    Biomark Med; 2010 Aug; 4(4):535-41. PubMed ID: 20701442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy.
    Li X; Song W; Shao C; Shi Y; Han W
    Cell Mol Immunol; 2019 Jan; 16(1):28-39. PubMed ID: 30002451
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiotherapy, tumor mutational burden, and immune checkpoint inhibitors: time to do the math.
    Giordano FA; Veldwijk MR; Herskind C; Wenz F
    Strahlenther Onkol; 2018 Oct; 194(10):873-875. PubMed ID: 30030581
    [No Abstract]   [Full Text] [Related]  

  • 33. Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.
    Zhu J; Armstrong AJ; Friedlander TW; Kim W; Pal SK; George DJ; Zhang T
    J Immunother Cancer; 2018 Jan; 6(1):4. PubMed ID: 29368638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune Checkpoint Inhibitors: Basics and Challenges.
    Li B; Chan HL; Chen P
    Curr Med Chem; 2019; 26(17):3009-3025. PubMed ID: 28782469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Skin Reactions to Immune Checkpoint Inhibitors.
    Patel AB; Pacha O
    Adv Exp Med Biol; 2017; 995():175-184. PubMed ID: 28321818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Do immune checkpoint inhibitors increase sensitivity to salvage chemotherapy?
    Saleh K; Khalifeh-Saleh N; Kourie HR; Nasr F; Chahine G
    Immunotherapy; 2018 Mar; 10(3):163-165. PubMed ID: 29370724
    [No Abstract]   [Full Text] [Related]  

  • 37. Next generation predictive biomarkers for immune checkpoint inhibition.
    Khagi Y; Kurzrock R; Patel SP
    Cancer Metastasis Rev; 2017 Mar; 36(1):179-190. PubMed ID: 27873079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers.
    Lhuillier C; Vanpouille-Box C; Galluzzi L; Formenti SC; Demaria S
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):125-134. PubMed ID: 29258856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unique issues in the development of "targeted" antineoplastic pharmaceutical agents.
    Markman M
    Curr Oncol Rep; 2005 Jul; 7(4):235-6. PubMed ID: 15946580
    [No Abstract]   [Full Text] [Related]  

  • 40. Cutting-edge cancer drug hobbled by diagnostic test confusion.
    Ledford H
    Nature; 2018 Apr; 556(7700):161-162. PubMed ID: 29636574
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.